Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

PDC*line Pharma, a clinical-stage biotech company developing a new class of immunotherapies for cancers, presented the ...

Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

The new promising data presented by Martin Forster, M.D., Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

To that end, it has even already gone on to report an increase in response rate when Cretostimogene was given in combination ...

Rucaparib Maintenance Improves Long-Term Outcomes in Ovarian Cancer Rucaparib maintenance after first-line chemotherapy and ...